Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Denali Therapeutics (DNLI) Equity Average (2018 - 2025)

Denali Therapeutics (DNLI) has disclosed Equity Average for 8 consecutive years, with $970.0 million as the latest value for Q4 2025.

  • Quarterly Equity Average fell 23.87% to $970.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $970.0 million through Dec 2025, down 23.87% year-over-year, with the annual reading at $1.1 billion for FY2025, 0.76% down from the prior year.
  • Equity Average for Q4 2025 was $970.0 million at Denali Therapeutics, down from $976.6 million in the prior quarter.
  • The five-year high for Equity Average was $1.4 billion in Q2 2024, with the low at $847.9 million in Q3 2022.
  • Average Equity Average over 5 years is $1.1 billion, with a median of $1.1 billion recorded in 2023.
  • The sharpest move saw Equity Average soared 139.94% in 2021, then decreased 27.81% in 2025.
  • Over 5 years, Equity Average stood at $987.3 million in 2021, then dropped by 6.12% to $926.9 million in 2022, then grew by 15.94% to $1.1 billion in 2023, then grew by 18.56% to $1.3 billion in 2024, then fell by 23.87% to $970.0 million in 2025.
  • According to Business Quant data, Equity Average over the past three periods came in at $970.0 million, $976.6 million, and $1.1 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.